TYTakashi Yoshida

Takashi Yoshida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takashi Yoshida has a total of 278 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development and internal validation of machine-learning models to predict adverse pathological features in upper tract urothelial carcinoma

    by Philipp Korn, Maximilian Pallauf, Soum Lokeshwar, Giacomo Musso, Zhenje Wu, Linhui Wang, Alex Kutikov, Randall Lee, Francesco Ditonno, Alessandro Veccia, et al.

  • Oncological outcomes of radical nephroureterectomy with or without lymphadenectomy and neoadjuvant therapy in cN+ UTUC: Insights from the ROBUUST registry

    by Francesco Passaro, Roberto Contieri, Antonio Tufano, Gianluca Spena, Gabriele Bignante, Srinivas Vourganti, Giuseppe Simone, Gabriele Tuderti, Zhenjie Wu, Linhui Wang, et al.

  • Open Access

    HMGA2 links morphological evolution and microenvironment dynamics to systemic therapy response in clear cell renal cell carcinoma

    by Takahiro Nakamoto, Takashi Yoshida, Chisato Ohe, Yoshiki Yasukochi, Naho Atsumi, Takeshi Sano, Koichiro Higasa, Katsunori Uchida, Koji Tsuta, Hidefumi Kinoshita

    Background: Clear cell renal cell carcinoma (ccRCC) exhibits significant heterogeneity due to morphological changes and tumor microenvironment dynamics, influencing systemic therapy responses. While the role of high-mobility group AT-hook 2 (HMGA2) in tumor progression has been implicated in other cancers, its significance in ccRCC remains unclear. This study investigates the role of HMGA2 in these processes and its clinical impact. Methods: Spatial transcriptomics (ST) was performed on primary ccRCC samples to investigate expression trajectories associated with HMGA2 expression and morphological evolution. In metastatic ccRCC cohorts treated with systemic therapy, immunohistochemistry and bulk RNA sequencing data were analyzed to evaluate molecular and clinical features in relation to HMGA2 . Single-cell RNA sequencing (scRNA-seq) data were used to explore immune cell populations and their interactions. Based on these findings, multiplex immunohistochemistry (mIHC) assessed spatial distribution, cell–cell interactions, and pathological responses of key immune populations. Results: HMGA2 expression was associated with aggressive morphological patterns, such as solid sheets and rhabdoid/sarcomatoid. ST revealed a progressive increase in HMGA2 expression along the morphological trajectory, marked by a shift from clear to eosinophilic cytoplasm, with eccentric nuclei and prominent nucleoli, and loss of vascular architecture. HMGA2 -high tumors exhibited aggressive phenotypes driven by cell cycle, epithelial-mesenchymal transition, and inflammatory signaling pathways. Clinically, patients with high HMGA2 had worse progression-free survival but responded better to immune checkpoint inhibitor combination (Combo-ICI) therapy than to tyrosine kinase inhibitor monotherapy. To assess the immune landscape, scRNA-seq data revealed that HMGA2 -high tumors were enriched with progenitor exhausted CD8 + T cells (Tpex), along with increased frequencies of conventional dendritic cell type 1 (cDC1) and inflammatory cDC type 2, which were found to interact with Tpex via ICAM-1 . mIHC confirmed that Tpex were enriched among Combo-ICI responders in HMGA2-high tumors, with higher densities and closer proximity to ICAM-1 + cDC1. Conclusions: These findings suggest that dynamic HMGA2 expression contributes to morphological evolution and modulates immune responses through enhanced Tpex–cDCs engagement, serving as a potential marker for systemic therapy response in ccRCC. However, additional experimental studies are required to validate these mechanisms.


  • Curative approach for solitary liver metastasis presenting as a rare pattern of organ spread in testicular cancer: a case report

    by Sho Kiyota, Takashi Yoshida, Takahiro Nakamoto, Chisato Ohe, Yumiko Kono, Akiyo Kita, Yuki Masuo, Hidefumi Kinoshita

    Solitary liver metastasis is an uncommon presentation of metastatic testicular cancer. This report details the case of a 16-year-old boy who presented with high fever and slight enlargement of the left testicle. Imaging revealed para-aortic regional lymph node swelling and a large liver mass occupying most of the left lobe. Left radical inguinal orchiectomy was performed, followed by liver biopsy to distinguish between a primary tumor and distant metastasis. Histopathological analysis confirmed a mixed non-seminomatous germ cell tumor with liver metastasis. The patient underwent four cycles of combination chemotherapy with bleomycin, etoposide, and cisplatin, followed by two additional cycles of etoposide, ifosfamide, and cisplatin, until tumor marker negativity was confirmed. Despite chemotherapy, clinically significant residual masses remained in the regional lymph nodes and liver. Detailed imaging evaluation suggested that liver metastasis had occurred through mesenteric vein infiltration by para-aortic lymph node metastasis. Retroperitoneal lymph node dissection was performed, revealing no evidence of malignancy, followed by liver metastasectomy. The patient achieved complete remission and has remained recurrence-free for 4 years since multimodal therapy. Even in the cases of liver metastases associated with poor prognosis, a comprehensive therapeutic approach that considers the metastatic pathway can achieve curative outcomes.

  • Open Access

    New Insights into Upper Tract Urothelial Carcinoma: Lessons Learned from the ROBUUST Collaborative Study

    by Arianna Biasatti, Gabriele Bignante, Francesco Ditonno, Alessandro Veccia, Riccardo Bertolo, Alessandro Antonelli, Randall Lee, Daniel D. Eun, Vitaly Margulis, Firas Abdollah, et al.

    Upper tract urothelial carcinoma (UTUC) is a rare malignancy, representing only 5–10% of urothelial carcinoma. The mainstay of treatment for high-risk patients is radical nephroureterectomy. Given the aggressive behavior of this disease, additional treatments could be required perioperatively in terms of chemotherapy (CHT), either in a neoadjuvant or adjuvant setting. On the other hand, low-risk and selected cases can be managed with kidney-sparing surgery (KSS). The ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) is an ongoing international, multicenter registry of patients undergoing surgery for UTUC. After conducting a literature search in February 2025 using the MEDLINE (via PubMed) and Embase databases, we identified 14 studies based on the ROBUUST data analyses. There are several key topics concerning UTUC that remain under debate and were therefore addressed in these studies, focusing on preoperative evaluation and planning, surgical techniques and intraoperative procedures, additional perioperative treatments, and outcomes. The ROBUUST registry has served as a valuable source for a growing body of investigations focusing on various aspects of UTUC treatment planning, decision-making, and outcomes, providing innovative tools and enabling large-scale, novel analyses.


  • Open Access

    Photodynamic Diagnosis-Guided Ureteroscopic Laser Ablation of Upper Urinary Tract Urothelial Carcinoma: Phase 2, Open-Label, Single-Arm Trial

    by Takashi Yoshida, Yusuke Motoki, Craig G. Rogers, Johar Raza, Takahiro Nakamoto, Tadashi Matsuda, Hidefumi Kinoshita


  • Open Access

    Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study

    by Sho Kiyota, Takashi Yoshida, Takahiro Nakamoto, Eri Jino, Takao Mishima, Hidefumi Kinoshita

    Renal cell carcinoma (RCC) affects 10%–20% of patients annually, often with metastases present. This study evaluated the impact of systemic therapy before nephrectomy in patients with unresectable or metastatic renal cell carcinoma (RCC). Patients receiving upfront immune checkpoint inhibitor (ICI) combination therapy showed significantly improved progression‐free survival (PFS) compared to nephrectomy alone (2‐year PFS: 62.3% vs. 17.4%; p = 0.036), while upfront tyrosine kinase inhibitor (TKI) therapy did not (2‐year PFS: 18.2% vs. 12.3%; p = 0.545). Surgery‐related outcomes did not differ significantly between groups. ICI therapy maintained tumour reduction rates better than TKI therapy. The study highlights the potential benefits of ICI combination therapy over TKI therapy in advanced RCC, suggesting further research is needed to confirm these findings.


  • Open Access

    Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma

    by Takashi Yoshida, Takahiro Nakamoto, Naho Atsumi, Chisato Ohe, Takeshi Sano, Yoshiki Yasukochi, Koji Tsuta, Hidefumi Kinoshita

    Background: Anti-programmed death-1 (PD-1)/anti-PD-ligand-1 (PD-L1) pathway inhibition is a standard regimen for advanced urothelial carcinoma (UC); however, its limited efficacy has been reflected in reported medium response rates. This study explored the role of next-generation coinhibitory receptors (IRs; lymphocyte activation gene 3 (LAG-3), T-cell immunoglobulin and mucin domain 3 (TIM-3), and T-cell immunoreceptor with Ig and ITIM domains (TIGIT)) and their ligands (LGs) in the response to PD-(L)1 blockade therapy and the oncological outcomes in patients with UC. Methods: We investigated metastatic UC cases who underwent PD-(L)1 therapy (cohort 1: n=348, cohort 2: n=89, and cohort 4: n=29) or advanced UC cases involving surgery (cohort 3: n=293 and cohort 5: n=90). We assessed the mRNA expression profiles and corresponding clinical information regarding IRs and LGs using cohorts 1, 2, and 3. Additionally, we elucidated the spatial features of these targeted markers using multiplex immunohistochemistry (mIHC) on formalin-fixed paraffin-embedded samples from cohorts 4 and 5. Survival, differential expressed gene, and Gene Set Enrichment analyses were performed. For mIHC, quantitative analyses were also performed to correlate immune and tumor cell densities with patient survival. Results: LAG-3 expression was strongly associated with the responsiveness of PD-(L)1 blockade compared with the expression of TIM-3 and TIGIT. In tumors with high LAG-3 levels, the increased expression of fibrinogen-like protein 1 (FGL1) had a significantly negative effect on the response to PD-(L)1 blockade and overall survival. Moreover, high FGL1 levels were associated with elevated CD4+ regulatory T-cell gene signatures and the upregulation of CD39 and neuropilin-1, with both indicating CD8+ T-cell exhaustion. mIHC analyses revealed that patients with stromal CD8+LAG-3+cellshigh–tumor FGL1+cellshigh exhibited a significant negative correlation with survival rates compared with those with stromal CD8+LAG-3+cellshigh–tumor FGL1+cellslow. Conclusions: LAG-3 expression and high FGL1 coexpression are important predictive factors of adverse oncological outcomes related to the presence of immunosuppressive contextures. These findings are hypothesis-generating, warranting further mechanistic and clinical studies aimed to evaluate LAG-3/FGL1 blockade in UC.